The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)

Source : https://www.sciencedirect.com/science/article/pii/S266637912030241X

KRAS, an oncogenic driver in lung cancer, is known as an "undruggable" target Different strategies are under investigation to indirectly and directly target KRAS Clinical trials of small-molecule inhibitors report promising interim results KRAS is a frequent oncogenic driver in solid tumors, including non-small cell lung cancer (NSCLC).